Montelukast Prevents Early Diabetic Retinopathy in Mice

Area of Science:

• Ophthalmology
• Pharmacology
• Diabetology

Background:

• Diabetic retinopathy (DR) pathogenesis involves chronic inflammation and oxidative stress, leading to neuronal and vascular damage.
• Early DR is characterized by microvascular changes and neuronal degeneration, impacting vision.
• The leukotriene cascade is implicated in inflammatory processes contributing to DR.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting the leukotriene cascade in early diabetic retinopathy.
• To assess the effects of montelukast, a leukotriene receptor antagonist, on diabetes-related retinal pathology in a mouse model.

Main Methods:

• Utilized the streptozotocin-induced diabetes mouse model.
• Administered montelukast to diabetic mice.
• Evaluated early biochemical and cellular markers (vascular permeability, superoxide, leukotriene generation, endothelial cell death) at 3 months.
• Assessed histopathology (capillary degeneration, retinal ganglion cell loss) at 9 months.
• Measured retinal function using electroretinography.

Main Results:

• Montelukast significantly reduced early diabetes-induced retinal capillary leakage, superoxide generation, leukocyte adherence, and leukotriene generation.
• Untreated diabetic mice showed a threefold increase in capillary degeneration after 9 months compared to controls.
• Montelukast inhibited both capillary and neuronal degeneration, regardless of administration timing (prevention or intervention).

Conclusions:

• Pharmacologic blockade of the leukotriene pathway is a promising therapeutic strategy for diabetic retinopathy.
• Montelukast demonstrated efficacy in preventing or slowing the progression of diabetic retinopathy in a preclinical model.
• Targeting the leukotriene pathway offers a novel approach to managing diabetic eye disease.